Drugs by condition
Drugs approved for myelofibrosis
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
5
Still marketed, NDA or BLA
Drug classes
2
Novel drugs
4
New molecular entities and new biologics
In development
12
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for myelofibrosis.
- Jakafi Xr (Ruxolitinib Phosphate) · Incyte Corp OrphanMay 1, 2026
- Ojjaara (Momelotinib Dihydrochloride) · Glaxosmithkline NovelOrphanSep 15, 2023
- Vonjo (Pacritinib Citrate) · Sobi NovelAccelerated approvalPriority reviewOrphanFeb 28, 2022
- Inrebic (Fedratinib Hydrochloride) · Bristol-Myers NovelPriority reviewOrphanAug 16, 2019
- Jakafi (Ruxolitinib Phosphate) · Incyte Corp NovelPriority reviewOrphanNov 16, 2011
All approved drugs for myelofibrosis, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Kinase Inhibitor (3)
Class not listed in FDA's data (2)
Drugs in development for myelofibrosis
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- RovadicitinibTQ05105Phase 35 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- roginolisibIOA-244Phase 23 trials
iOnctura · Myelofibrosis (MF), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC
- BMS-986158Phase 22 trials
Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- amsulostatPXS-5505Phase 21 trial
Syntara · Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis
- GB2064Phase 21 trial
Galecto Biotech AB · Myelofibrosis
- TL-895Phase 21 trial
Telios Pharma, Inc. · Myelofibrosis, Primary Myelofibrosis, Post-PV MF
- TQB3617Phase 21 trial
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Myelofibrosis
More on myelofibrosis: recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Sickle cell disease · Hemophilia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.